- Drugs
- Wednesday, 18 Dec 2019
Medical Marijuana, Inc. Appoints New Chief Financial Officer
Medical Marijuana, Inc. (OTC: MJNA) (the "Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that it has promoted its VP of Corporate Finance Brooke Beers to Chief Financial Officer of the Company.
"Brooke's contributions to the Company have been extraordinary," said Medical Marijuana, Inc. COO Blake Schroeder. "He's helped us overcome several financial obstacles that many cannabis companies face every day and he has helped us significantly improve our public reporting practices to increase transparency."
Beers was hired by Medical Marijuana, Inc. in 2017 and has since been leading the Company's accounting department, handling the Company's budget management, public financial reports, e-commerce offerings, and forecasting needs.
"Working with the Medical Marijuana, Inc. team has been an incredibly rewarding experience," said Beers. "Last December, the Brightfield Group reported that our Company represents 10 percent of the entire CBD market and I'm proud to be a part of that financial milestone and many more to come. It's encouraging to work with a large group of highly motivated professionals and claim our stake in the global CBD industry."
Related Industry Updates
Malaria and Sickle Cell Disease Treatment Market is expected to reach US$ 29,179.60 million by 2030
Nov 03, 2023
Celltrion Launches Liquid Remsima IV in Europe to Lead Infliximab Market
Mar 12, 2026
Transdermal Medical Patch Market is expected to reach US$ 10,799.74 million by 2028
Jun 06, 2023
Europe pharmaceutical drug delivery market is expected to reach US$ 562,102.6 Mn by 2027
Oct 06, 2020
Herbal Medicine plays a significant role in Healing the Nervous System
Apr 03, 2020
US Pharmacy Management System Market is expected to reach US$ 53,139.59 million by 2030
Sep 21, 2023
Innovent and Lilly Collaborate to Advance Novel Medicines
Feb 09, 2026